GRANISETRON AS ANTIEMETIC THERAPY IN CHILDREN WITH CANCER

被引：18

作者：

CRAFT, AW

PRICE, L

EDEN, OB

SHAW, P

CAMPBELL, R

PIERCE, DM

MURDOCH, R

UPWARD, J

机构：

[1] UNIV NEWCASTLE UPON TYNE,CHILDRENS CANC UNIT,NEWCASTLE TYNE NE1 7RU,TYNE & WEAR,ENGLAND

[2] ROYAL HOSP SICK CHILDREN,DEPT PAEDIAT HEMATOL ONCOL,EDINBURGH EH9 1LF,MIDLOTHIAN,SCOTLAND

[3] FREEMAN RD HOSP,DEPT CARDIOL,NEWCASTLE TYNE NE7 7DN,TYNE & WEAR,ENGLAND

来源：

MEDICAL AND PEDIATRIC ONCOLOGY | 1995年 / 25卷 / 01期

关键词：

ANTIEMETICS; CANCER; CHILDREN; EMETOGENIC CHEMOTHERAPY;

D O I：

10.1002/mpo.2950250107

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The safety and efficacy of the new 5HT-3 antagonist granisetron as an antiemetic in children with cancer was evaluated in 40 children at a single doses of 40 mug/kg. No adverse affects attributable to the granisetron were noted. The overall major and complete response rate was 82.5% and this was highest in the younger children. Only 2 patients showed no response. Pharmacokinetic studies showed associations between some pharmacokinetic parameters and age which were no longer apparent after normalisation for body weight. Granisetron is an effective and very well-tolerated antiemetic and appears to be an important addition to the supportive care available for children with cancer. (C) 1995 Wiley-Liss, Inc.

引用

页码：28 / 32

页数：5

共 7 条

[1] MODFIT - A PHARMACOKINETICS COMPUTER-PROGRAM [J].

ALLEN, GD .

BIOPHARMACEUTICS & DRUG DISPOSITION, 1990, 11 (06) :477-498

[2]

CARMICHAEL J, 1989, CANCER CHEMOTH PHARM, V24, P45

[3]

CLARKSON A, 1988, BR J CLIN PHARM, V25, pP125

[4] EFFICACY AND SAFETY OF GRANISETRON IN THE PREVENTION OF CHEMOTHERAPY-INDUCED EMESIS IN PEDIATRIC-PATIENTS [J].

LEMERLE, J ;

AMARAL, D ;

SOUTHALL, DP ;

UPWARD, J ;

MURDOCH, RD .

EUROPEAN JOURNAL OF CANCER, 1991, 27 (09) :1081-1083

[5]

SOUKOP M, 1990, EUR J CANCER, V26, P16

[6]

UPWARD JW, 1990, EUR J CANCER, V26, P13

[7]

SAS STAT USERS GUIDE, V2

← 1 →